Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Prolonged In-use Stability of Diluted Atezolizumab in Commerical Intravenous Bags

Author(s):  Hui Ada, Yin Jian, Liu Wei, Zheng Kai

Issue:  May/Jun 2021 - Volume 25, Number 3
View All Articles in Issue

Abstract:  The programmed death-ligand 1 checkpoint inhibitor, atezolizumab is a monoclonal antibody that is indicated for the treatment of several cancers. Prior to administration, atezolizumab is diluted in normal saline (0.9% sodium chloride) in polyvinylchloride or polyolefin infusion bags. The objective of the studies reported in this paper was to evaluate the stability of atezolizumab diluted to 2.4 mg/mL and 9.6 mg/mL (Study 1), and 16.8 mg/mL (Study 2) in intravenous bags containing normal saline and stored for up to 12 months. Atezolizumab was withdrawn from commercial vials (1,200 mg/20 mL or 840 mg/14 mL) under aseptic conditions and added to infusion bags containing normal saline with target concentrations of 2.4 mg/mL, 9.6 mg/mL, and 16.8 mg/mL. Bags were stored at 30°C for 24 hours with exposure to ambient light, then at 2°C to 8°C for up to 12 months protected from light. 10-mL samples were withdrawn at selected time points and evaluated by analytical assays for color, opalescence, and clarity; visible and subvisible particulates; pH; protein concentration by ultraviolet spectrophotometric analysis; size-exclusion high-performance liquid chromatography; ion-exchange high-performance liquid chromatography; non-reduced capillary electrophoresis-sodium dodecyl sulfate; and potency assays. No substantial changes in atezolizumab product quality were apparent by any measure related to any analytical assay in either study after 3 months of storage at 2°C to 8°C. No new peaks were observed on size-exclusion high-performance liquid chromatography, ion-exchange high-performance liquid chromatography, or non-reduced capillary Funding Acknowledgment This study was funded by Genentech, Inc., South San Francisco, California. electrophoresis-sodium dodecyl sulfate profiles of diluted atezolizumab after the extended storage of 12 months at 2°C to 8°C. In Study 1, a decreasing trend in ion-exchange high-performance liquid chromatography main peak area was detected in samples from polyvinylchloride bags containing 2.4 mg/mL atezolizumab; and substantial changes were observed at 12 months in samples from polyvinylchloride bags containing 2.4 mg/mL and 9.6 mg/mL atezolizumab. In Study 2, decreasing trends in main peak areas were detected by size-exclusion high-performance liquid chromatography analyses, ion-exchange high-performance liquid chromatography analyses, and nonreduced capillary electrophoresis-sodium dodecyl sulfate analyses of samples stored in polyvinylchloride bags, where substantial changes were observed in size exclusion high-performance liquid chromatography main peak area at 12 months and in ion-exchange high-performance liquid chromatography main peak areas at the 6-month and subsequent time points. Decreasing trends in main peak areas were detected by ion-exchange high-performance liquid chromatography analyses and non-reduced capillary electrophoresis-sodium dodecyl sulfate analyses of samples taken from polyolefin bags, where substantial changes were observed in ion-exchange high-performance liquid chromatography main peak areas at 6 and 12 months. In conclusion, atezolizumab diluted to 2.4 mg/mL to 16.8 mg/mL in 0.9% sodium chloride remains physicochemically stable when stored for 24 hours at 30°C, followed by 3 months at 2°C to 8°C in polyvinylchloride and polyolefin infusion bags.

Related Keywords: Ada Hui, BS, Jian Yin, MS, Wei Liu, PhD, Kai Zheng, PhD, atezolizumab, programmed death ligand 1 checkpoint inhibitor, monoclonal antibody, cancer treatment, stability, infusion bags


Printer-Friendly Version

Download in electronic PDF format for $45

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Prolonged In-use Stability of Diluted Atezolizumab in Commerical Intravenous Bags Hui Ada, Yin Jian, Liu Wei, Zheng Kai May/Jun 2021 246-257 Buy
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Nalenz Heiko, Köpf Ellen, Dietel Elke Sep/Oct 2018 417-423 Buy
Stability of Ampicillin Sodium, Nafcillin Sodium, and Oxacillin Sodium in AutoDose Infusion System Bags Zhang Yanping, Trissel Lawrence A May/Jun 2002 226-229 Buy
Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags Kaiser Jeanette, Kramer Irene Nov/Dec 2011 515-520 Buy
In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers Bhattacharya Sisir, Parekh Satish, Dedhiya Mahendra Sep/Oct 2015 432-436 Buy
Stability of Gentamicin Sulfate and Tobramycin Sulfate in AutoDose Infusion System Bags Xu Quanyun A, Trissel Lawrence A, Saenz Christopher A, Ingram Delshalonda S Mar/Apr 2002 152-154 Buy
Sensitization Therapy for Warts Kuntz Rachael Jul/Aug 2003 266-270 Buy
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags Breukels Oscar, van der Gronde Toon, Simons-Sanders Kathleen, Crul Mirjam Jul/Aug 2018 345-349 Buy
Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S Jan/Feb 2021 73-81 Buy
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags Marquis Kathleen, Hohlfelder Benjamin, Szumita Paul M Sep/Oct 2017 436-439 Buy